FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ingrid Langer

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Cricetinae

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Physiology

Phenomena

Protein Binding

Co-author Network

Publications

TOP 3
Ingrid Langer
Conformational switches in the VPAC(1) receptor.
Ingrid Langer
Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.
Anton O Chugunov; John Simms; David R Poyner; Yves Dehouck; Marianne Rooman; Dimitri Gilis; Ingrid Langer
Evidence that interaction between conserved residues in transmembrane helices 2, 3, and 7 are crucial for human VPAC1 receptor activation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ingrid Langer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Ingrid Langer
Conformational switches in the VPAC(1) receptor.
British journal of pharmacology 2012;166(1):79-84.
2012: Ingrid Langer
Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.
Frontiers in endocrinology 2012;3():129.
2010: Anton O Chugunov; John Simms; David R Poyner; Yves Dehouck; Marianne Rooman; Dimitri Gilis; Ingrid Langer
Evidence that interaction between conserved residues in transmembrane helices 2, 3, and 7 are crucial for human VPAC1 receptor activation.
Molecular pharmacology 2010;78(3):394-401.
2008: Ingrid Langer; Karelle Leroy; Nathalie Gaspard; Jean-Pierre Brion; Patrick Robberecht
Cell surface targeting of VPAC1 receptors: evidence for implication of a quality control system and the proteasome.
Biochimica et biophysica acta 2008;1783(9):1663-72.
2007: Ingrid Langer; Patrick Robberecht
Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors.
Biochemical Society transactions 2007;35(Pt 4):724-8.
2006: Ingrid Nachtergael; Nathalie Gaspard; Christelle Langlet; Patrick Robberecht; Ingrid Langer
Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
Cellular signalling 2006;18(12):2121-30.
2006: Ingrid Langer; Nathalie Gaspard; Patrick Robberecht
Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2).
British journal of pharmacology 2006;148(8):1051-9.
2006: Christelle Langlet; Ingrid Nachtergael; Patrick Robberecht; Ingrid Langer
Mutation of the phosphorylatable residue Thr429 in Glu of the human VPAC1 led to a constitutively desensitized receptor.
Peptides 2006;27(7):1865-70.
2005: Christelle Langlet; Ingrid Langer; Pascale Vertongen; Nathalie Gaspard; Jean-Marie Vanderwinden; Patrick Robberecht
Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling.
The Journal of biological chemistry 2005;280(30):28034-43.
2005: Ingrid Langer; Christelle Langlet; Patrick Robberecht
Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
Journal of molecular endocrinology 2005;34(2):405-14.
2005: Ingrid Langer; Patrick Robberecht
Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
Cellular signalling 2005;17(1):17-24.
2004: Christelle Langlet; Nathalie Gaspard; Ingrid Nachtergael; Patrick Robberecht; Ingrid Langer
Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells.
Peptides 2004;25(12):2079-86.
2004: Pascale Vertongen; Christelle Langlet; Ingrid Langer; Nathalie Gaspard; Patrick Robberecht
Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Peptides 2004;25(11):1943-9.
2004: Ingrid Langer; Françoise Gregoire; Ingrid Nachtergael; Philippe De Neef; Pascale Vertongen; Patrick Robberecht
Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
Peptides 2004;25(2):275-8.
2003: Ingrid Nachtergael; Pascale Vertongen; Ingrid Langer; Jason Perret; Patrick Robberecht; Magali Waelbroeck
Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
The Biochemical journal 2003;370(Pt 3):1003-9.
2003: Ingrid Langer; Pascale Vertongen; Jason Perret; Magali Waelbroeck; Patrick Robberecht
Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists.
Neuropharmacology 2003;44(1):125-31.
2002: Ingrid Langer; Pascale Vertongen; Jason Perret; Magali Waelbroeck; Patrick Robberecht
A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.
Biochemical Society transactions 2002;30(4):447-50.
2002: Jason Perret; Pascale Vertongen; RM Solano; Ingrid Langer; Johnny Cnudde; Patrick Robberecht; Magali Waelbroeck
Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.
British journal of pharmacology 2002;136(7):1042-8.
2002: Ingrid Langer; Pascale Vertongen; Jason Perret; Johnny Cnudde; Françoise Gregoire; Philippe De Neef; Patrick Robberecht; Magali Waelbroeck
VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells.
Cellular signalling 2002;14(8):689-94.
2002: Ingrid Langer; Pascale Vertongen; Jason Perret; Magali Waelbroeck; Patrick Robberecht
A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.
Molecular endocrinology (Baltimore, Md.) 2002;16(5):1089-96.
2002: Jason Perret; Mélanie Van Craenenbroeck; Ingrid Langer; Pascale Vertongen; Françoise Gregoire; Patrick Robberecht; Magali Waelbroeck
Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.
The Biochemical journal 2002;362(Pt 2):389-94.
2001: Roger Lema-Kisoka; N Hayez; Ingrid Langer; Patrick Robberecht; Eric Sariban; Christine Delporte
Characterization of functional VIP/PACAP receptors in the human erythroleukemic HEL cell line.
Peptides 2001;22(12):2155-62.
2001: Ingrid Langer; Jason Perret; Pascale Vertongen; Magali Waelbroeck; Patrick Robberecht
Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.
Cell calcium 2001;30(4):229-34.
2001: Pascale Vertongen; RM Solano; Jason Perret; Ingrid Langer; Patrick Robberecht; Magali Waelbroeck
Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
British journal of pharmacology 2001;133(8):1249-54.
2001: RM Solano; Ingrid Langer; Jason Perret; Pascale Vertongen; María G Juarranz; Patrick Robberecht; Magali Waelbroeck
Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction.
The Journal of biological chemistry 2001;276(2):1084-8.